3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Similar Items

• 3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
  by: Nevin John, et al.
  Published: (2024-08-01)
• Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
  by: Gavin Giovannoni, et al.
  Published: (2024-02-01)
• Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
  by: Mansour A. Alharbi, et al.
  Published: (2023-05-01)
• Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
  by: Helmut Butzkueven, et al.
  Published: (2020-10-01)
• 008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
  by: Steve Vucic, et al.
  Published: (2021-08-01)